UK Pharmaceuticals and Healthcare Market
Kay Gary
2014-03-27
Views 5
UK Pharmaceuticals and Healthcare Market
BMI View: The UK's health technology assessment and pricing/reimbursement decision making bodies are
looking to take an increasingly hard line when determining whether a new drug provides added value to
patients compared with existing therapies. However, with regards to the incoming value-based medicine
pricing system, we believe that providing a satisfactory definition of the word 'value' will be difficult and
companies will be faced with a challenging pricing environment. In the past, the National Institute for
Health and Care Excellence (NICE) has come under attack for its definition of cost effectiveness.
Headline Expenditure Projections
http://www.marketreportsonline.com/322612.html .
BMI View: The UK's health technology assessment and pricing/reimbursement decision making bodies are
looking to take an increasingly hard line when determining whether a new drug provides added value to
patients compared with existing therapies. However, with regards to the incoming value-based medicine
pricing system, we believe that providing a satisfactory definition of the word 'value' will be difficult and
companies will be faced with a challenging pricing environment. In the past, the National Institute for
Health and Care Excellence (NICE) has come under attack for its definition of cost effectiveness.
Headline Expenditure Projections
http://www.marketreportsonline.com/322612.html .
Report form
